Treos Bio
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
79 New Cavendish St, London, Greater Lon...Phone Number
(240) 505-4396Website
www.treosbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Treos Bio
Treos Bio is a clinical stage company focused on developing next-generation off-the-shelf peptide active cancer immunotherapies that address tumor and patient heterogeneity. Their proprietary therapeutic peptides stimulate effective cancer-specific immune responses across genetically diverse patient populations without the need for tumor biopsies. The company's lead product, PolyPEPI1018, targets colorectal cancer and has shown promising results in inducing robust immunological responses. Treos Bio aims to revolutionize cancer treatment by making their innovative therapies accessible to patients worldwide.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Treos Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Treos Bio recently announced quarterly report
Click to see if Treos Bio had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Treos Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Treos Bio has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Treos Bio
Website visits: Recent activity has been detected on your website
Check out if Treos Bio is spiking on competitors!
Product Launch: Get notified when Treos Bio launches new products
Funding: Get notified immidiatlly once Treos Bio has new funding data
Recommended Actions
Find VP level buyers at Treos Bio
Find more new buyers
Compare Similar Companies to Treos Bio
Compare insights from companies similar to Treos Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Treos Bio
<$5M
11-50
Private
$22M
2013
N/A
Company Profile Activity
Activity Insights
Treos Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Treos Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Treos Bio.
Treos Bio financials insights
Gather financial insights about Treos Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Private Equity
$8M
2021
Debt
$14M
Treos Bio Tech Stack
A closer look at the technologies used by Treos Bio
Treos Bio News & Media
TREOS Bio Announces Publication of Phase 1b Clinical Trial Results of PolyPEPI1018 Plus TAS-102 in Refractory MSS mCRC in JCO Oncology Advances
First study to report promising activity for an active immunotherapy combined with TAS-102 (LONSURF®) in late-stage MSS mCRC; TREOS advances Phase II programme with Charité – Universitätsmedizin Berlin and Junshi Biosciences First study to report promising activity for an active immunotherapy combined with TAS-102 (LONSURF®) in late-stage MSS mCRC; TREOS advances Phase II programme with Charité – Universitätsmedizin Berlin and Junshi BiosciencesTREOS Bio Partners with Charité Berlin and Junshi Biosciences to Launch Pivotal Phase II Clinical Trial in Refractory MSS Colorectal Cancer
Bridge financing of $2.1 million supports initiation of pivotal Phase II study in 140 patients with microsatellite stable metastatic colorectal cancer, addressing 85% of CRC cases with limited treatment options Bridge financing of $2.1 million supports initiation of pivotal Phase II study in 140 patients with microsatellite stable metastatic colorectal cancer, addressing 85% of CRC cases with limited treatment optionsNew Meta-Analysis Shows Treos Bio’s Promiscuous Epitopes in Their Off-The-Shelf Colorectal Cancer Immunotherapy Produce Stronger Immune Response than Traditional Epitopes
LONDON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Treos Bio announced the results of a meta-analysis from three clinical trials evaluating its investigational off-the-shelf immunotherapy, PolyPEPI1018, for the treatment of microsatellite stable metastatic colorectal cancer (MSS mCRC). The analysis revealed that prioritized peptides, selected using Treos' proprietary computational technology, were key in driving immune responses and clinical outcomes across the studies.At ASCO 2024, Treos Bio Reports Key Survival Results for Chemo-Free Regimen of PolyPEPI1018 Peptide Immunotherapy and Roche’s PD-L1 Inhibitor in Late-Stage Colorectal Cancer
Treos Bio reports promising survival results for chemo-free PolyPEPI1018 cancer vaccine combined with Roche's PD-L1 inhibitor in MSS mCRC at 2024 ASCO
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Treos Bio
Sign Up For FreeTo access detailed company insights
Treos Bio is a clinical stage company focused on developing next-generation off-the-shelf peptide active cancer immunotherapies that address tumor and patient heterogeneity. Their proprietary therapeutic peptides stimulate effective cancer-specific immune responses across genetically diverse patient populations without the need for tumor biopsies.... Read More
